This site is intended for health professionals only
Saturday 23 March 2019
Share |

Topic: schizophrenia

August 26, 2015
First long-acting treatment to be administered four times a year for the treatment of schizophrenia in adults

Janssen-Cilag International NV (Janssen) announced the submission of an extension marketing authorisation application (MAA) to the European Medicines Agency (EMA) for paliperidone palmitate once-every-three-months formulation for the treatment of schizophrenia. If approved, it will be the first antipsychotic schizophrenia medication to be administered four times a year.

 

March 31, 2015
Takeda Pharmaceuticals International GmbH and Sunovion Pharmaceuticals Inc. announced the results from three post-hoc analyses evaluating the efficacy and safety of Latuda® (lurasidone) in patients with schizophrenia at the 23rd European Congress of Psychiatry (EPA). The analyses suggest that lurasidone is associated with reduced hostility in patients with schizophrenia and reduced frequency of certain adverse events commonly associated with antipsychotic treatment.

Takeda Pharmaceuticals International GmbH and Sunovion Pharmaceuticals Inc. announced the results from three post-hoc analyses evaluating the efficacy and safety of Latuda® (lurasidone) in patients with schizophrenia at the 23rd European Congress of Psychiatry (EPA). The analyses suggest that lurasidone is associated with reduced hostility in patients with schizophrenia and reduced frequency of certain adverse events commonly associated with antipsychotic treatment.

May 9, 2014
H Lundbeck and Otsuka Pharmaceutical Europe Ltd announced results from the final analysis of a mirror-image study showing statistically significant reductions (p<0.0001) in total psychiatric hospitalisation rates in patients diagnosed with schizophrenia.

H Lundbeck and Otsuka Pharmaceutical Europe Ltd announced results from the final analysis of a mirror-image study showing statistically significant reductions (p<0.0001) in total psychiatric hospitalisation rates in patients diagnosed with schizophrenia.

The patients were switched from oral antipsychotics to Abilify Maintena® once-monthly 400 mg – a prolonged-release suspension for intramuscular injection of aripiprazole.(1)

October 8, 2010
Pharmaceutical giant Johnson & Johnson has asked a federal judge in the US to dismiss a complaint about the company regarding it paying millions of dollars in kickabouts to promote the use of its popular schizophrenia medication

teaser

November 18, 2009
Researchers at the Swedish medical university Karolinska Institutet have discovered that patients with recent-onset schizophrenia have higher levels of inflammatory substances in their brains

teaser

October 29, 2009
The schizophrenia drug cariprazine being developed by Hungarian producer Richter Gedeon with Forest Laboratories is showing positive phase IIb test results

teaser

October 21, 2009
Exposure to anti-epileptic drug (AED) treatment at key points in brain development increases schizophrenia-like behaviour

teaser

October 13, 2009
Novartis enters into agreement for exclusive US and Canadian rights to Fanapt, an FDA-approved oral therapy for schizophrenia

teaser

July 30, 2009
Lundbeck announced they have stopped the development of schizophrenia treatment bifrepunox with partner Solvay Pharaceuticals

teaser

July 29, 2009
US health chiefs have said that an experimental psychiatric drug appears to be a safe and effective treatment for people suffering from schizophrenia and bipolar disorder

teaser

July 14, 2009
People could have been prevented from dying after developing schizophrenia if they had been prescribed the anti-psychotic drug clozapine

teaser

May 20, 2009
British drugmaker facing allegations that it buried warnings from its own scientists regarding possible side-effects of the antipsychotic drug Seroquel

teaser

May 18, 2009
FDA action letter awaited for schizophrenia treatment drug

teaser

April 8, 2009
FDA Advisory Committee provides opinion on Serdolect for the treatment of schizophrenia

teaser

April 6, 2009
British pharmaceutical giant AstraZeneca is lobbying the US drugs regulator to approve a schizophrenia treatment

teaser

February 9, 2009
Johnson & Johnson announces FDA filings for paliperidone palmitate and Invega

teaser

January 16, 2009
Scientists believe schizophrenia and bipolar disorder could be part of the same mental illness

teaser

January 9, 2009
Anti-psychotic drugs found to double risk of death among Alzheimer's sufferers

teaser

November 26, 2008
Phase II trial for 5-HT6 receptor antagonist to complement extant schizophrenia treatments

teaser

October 22, 2008
Pharmaceutical company to pay for investigation into marketing practices for schizophrenia drug

teaser

September 30, 2008
Schizophrenia treatment Zypadhera recommended for approval in Europe

teaser

September 19, 2008
Irish firm to benefit from Biovail's acquisition of Prestwick Pharmaceuticals

teaser

September 16, 2008
First-generation schizophrenia medicine safer than newer treatments

teaser

August 7, 2008
Combining oestrogen with routine medication can ease schizophrenia symptoms finds study

teaser

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine